Journal
BIOMEDICINES
Volume 10, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10081918
Keywords
gastrointestinal cancer; RNA modification; therapeutic target
Categories
Funding
- Heath and Medical Research Fund (HMRF) [18190951]
- RGC-GRF Hong Kong [14107321]
- National Natural Science Foundation of China (NSFC) [82103245, 81972576]
- CUHK Direct Grant for Research [2020.006, 2021.004]
Ask authors/readers for more resources
This article summarizes the latest findings on the functional significance of RNA modification in GI cancer and discusses the potential therapeutic application of epitranscriptomic inhibitors for cancer treatment.
Gastrointestinal (GI) cancer, referring to cancers of the digestive system such as colorectal cancer (CRC), gastric cancer (GC), and liver cancer, is a major cause of cancer-related deaths in the world. A series of genetic, epigenetic, and epitranscriptomic changes occur during the development of GI cancer. The identification of these molecular events provides potential diagnostic, prognostic, and therapeutic targets for cancer patients. RNA modification is required in the posttranscriptional regulation of RNA metabolism, including splicing, intracellular transport, degradation, and translation. RNA modifications such as N6-methyladenosine (m6A) and N1-methyladenosine (m1A) are dynamically regulated by three different types of regulators named methyltransferases (writers), RNA binding proteins (readers), and demethylases (erasers). Recent studies have pointed out that abnormal RNA modification contributes to GI tumorigenesis and progression. In this review, we summarize the latest findings on the functional significance of RNA modification in GI cancer and discuss the therapeutic potential of epitranscriptomic inhibitors for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available